Based in Cambridge, MA, STRM.BIO (pronounced “storm bio”) is a pre-clinical, VC-backed biotechnology company that aims to fulfill the promise of gene therapy by leveraging extracellular vesicles (EVs) to deliver treatment directly to the patient (in vivo). Unlike viruses, EVs are natural carriers of nucleic acids and proteins with innate targeting capabilities, amenability to large scale/commercial manufacture, and low immunogenicity – which make them excellent cell messengers for gene therapies. Our proprietary EV platform is establishing a whole new class of therapeutics, yielding new therapies and making existing ones more effective. At STRM.BIO, we believe that our work has the potential to democratize gene therapy and bring hope for patients fighting rare diseases worldwide. We are currently recruiting team members who can help us make our vision a life-saving reality.
Location: United States
Employees: 11-50
Total raised: $8M
Founded date: 2019
Investors 4
| Date | Name | Website |
| - | KdT Ventur... | kdtvc.com |
| 01.10.2021 | Ascension ... | ascensionv... |
| - | NYBC Ventu... | nybcventur... |
| 24.08.2022 | Breakout V... | breakout.v... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.01.2026 | Seed | $8M | Delos Capi... |
Mentions in press and media 5
| Date | Title | Description |
| 11.01.2026 | STRM.BIO Secures $8M Seed 2, Propelling Non-Viral Gene Therapy Revolution | STRM.BIO, a Cambridge biotech, closed an $8M Series Seed 2 round. It drives non-viral gene therapy innovation. Its MV platform delivers genetic medicines for in vivo cell engineering. Total recent funding hit $16.4M. Funds advance the pipel... |
| 08.01.2026 | STRM.BIO: $8 Million Series Seed 2 Closed To Advance Non-Viral Gene Delivery For In Vivo Cell Engineering And Gene Therapy | STRM.BIO raised $8 million in a Series Seed 2 financing to advance its non-viral gene delivery platform for in vivo cell engineering and gene therapy. The round included funding from Recordati, with continued participation from Boehringer I... |
| 07.01.2026 | STRM.BIO Raises $8M in Series Seed 2 Financing | CAMBRIDGE, MA, STRM.BIO, a biotechnology company, announced $8 million in Series Seed 2 financing. >> Click here for more funding data on STRM.BIO >> To export STRM.BIO funding data to PDF and Excel, click here STRM.BIO, a biot... |
| 07.01.2026 | STRM.BIO Raises $8M in Series Seed 2 Financing | STRM.BIO, a Cambridge, MA-based biotechnology company advancing non-viral delivery technologies for in vivo cell and gene therapy, raised $8M in Series Seed 2 financing. The round was led by Recordati with participation form Boehringer Inge... |
| - | STRM.BIO | “Bringing Gene Therapy to Life” |